{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:16:57Z","timestamp":1792725417078,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Bromazolam is a new psychoactive substance (NPS) benzodiazepine commonly identified by drug checking services and in post\u2010mortem toxicological analyses in the United Kingdom, Europe, and North America. At the time of writing, there are no studies that present quantitative analyses of bromazolam in street tablets. Here we describe the first quantitative analysis of bromazolam tablets, from samples submitted by UK drug checking services and police forces between 2022 and 2025. Using validated GC\u2010EI\u2010MS and\n                    <jats:sup>1<\/jats:sup>\n                    H NMR methods, 47 tablet samples were quantified revealing a median bromazolam dose of 0.49\u2009mg (interquartile range\u2009=\u20091.02\u2009mg) per tablet, range of 0.09\u20135.4\u2009mg. Over half of the tablet submissions (55%) mimicked the appearance of licensed pharmaceuticals alprazolam or diazepam, raising significant concerns around mis\u2010selling of street bromazolam tablets and the risks of unintentional high\u2010dose exposure to an NPS compound. To contextualise these findings, we also report post\u2010mortem data from the UK National Programme on Substance Use Mortality (NPSUM), in which bromazolam was detected in 396 drug\u2010related deaths between April 2021 and July 2024. Bromazolam detections in deaths rose from 28 deaths in 2021 to 160 deaths in 2023. Bromazolam was implicated in causing death in 82.8% of cases, with a median post\u2010mortem blood concentration of 43\u2009ng\/mL. Notably, bromazolam was co\u2010detected with an average of seven other substances per case, most commonly other central nervous system (CNS) depressants. These findings underscore the public health risks posed by bromazolam as an NPS benzodiazepine and highlight the urgent need for monitoring, harm reduction and forensic toxicology guidance.\n                  <\/jats:p>","DOI":"10.1002\/dta.70045","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:12:48Z","timestamp":1772968368000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bromazolam Tablet Quantification and Analysis of Post\u2010Mortem Cases From the National Programme on Substance Use Mortality (NPSUM)"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5206-1259","authenticated-orcid":false,"given":"Matthew","family":"Gardner","sequence":"first","affiliation":[{"name":"Department of Life Sciences University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2543-3202","authenticated-orcid":false,"given":"Molly\u00a0F.","family":"Millea","sequence":"additional","affiliation":[{"name":"MANchester DRug Analysis &amp; Knowledge Exchange (MANDRAKE), Department of Natural Sciences Manchester Metropolitan University  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-2731","authenticated-orcid":false,"given":"Sam","family":"Craft","sequence":"additional","affiliation":[{"name":"Department of Psychology University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7836-036X","authenticated-orcid":false,"given":"Rachael","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Life Sciences University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4920-0914","authenticated-orcid":false,"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[{"name":"Centre for Academic Primary Care<sup>,<\/sup> Bristol Medical School University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-6322","authenticated-orcid":false,"given":"Stephen\u00a0M.","family":"Husbands","sequence":"additional","affiliation":[{"name":"Department of Life Sciences University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-0086","authenticated-orcid":false,"given":"Christopher\u00a0R.","family":"Pudney","sequence":"additional","affiliation":[{"name":"Department of Life Sciences University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-7754","authenticated-orcid":false,"given":"Oliver\u00a0B.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"MANchester DRug Analysis &amp; Knowledge Exchange (MANDRAKE), Department of Natural Sciences Manchester Metropolitan University  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-1402","authenticated-orcid":false,"given":"Caroline\u00a0S.","family":"Copeland","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science King's College London  London UK"},{"name":"National Programme on Substance Use Mortality  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5020-8251","authenticated-orcid":false,"given":"Peter","family":"Sunderland","sequence":"additional","affiliation":[{"name":"Department of Life Sciences University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2014.957186"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026023393444"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/81800"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2015_425"},{"key":"e_1_2_10_6_1","volume-title":"Drug\u2010Related Deaths in Scotland in 2021","author":"Lenton G.","year":"2022"},{"key":"e_1_2_10_7_1","unstructured":"EMCDDA (2024) https:\/\/www.euda.europa.eu\/publications\/eu\u2010drug\u2010markets\/new\u2010psychoactive\u2010substances\/distribution\u2010and\u2010supply\/benzodiazepines_en."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.111140"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13979"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.07.2684"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4417"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103512"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2021.1907303"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2170349"},{"key":"e_1_2_10_15_1","unstructured":"\u201cEducation CfFSRa \u201dhttps:\/\/www.cfsre.org\/nps\u2010discovery\/public\u2010alerts\/bromazolam\u2010prevalence\u2010surging\u2010across\u2010the\u2010united\u2010states\u2010driven\u2010in\u2010part\u2010by\u2010increasing\u2010detections\u2010alongside\u2010fentanyl."},{"key":"e_1_2_10_16_1","unstructured":"https:\/\/publichealthscotland.scot\/media\/20626\/radar_bromazola\u2010alert\u2010form\u2010july\u20102023\u2010english.pdf."},{"key":"e_1_2_10_17_1","unstructured":"https:\/\/www.wedinos.org\/resources\/downloads\/WEDINOS_Annual_Report_2023_2024_English.pdf."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9AY01403A"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.70110"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16671"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.4c08614"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkz063"},{"key":"e_1_2_10_23_1","unstructured":"https:\/\/www.gov.uk\/after\u2010a\u2010death\/when\u2010a\u2010death\u2010is\u2010reported\u2010to\u2010a\u2010coroner."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2023.111891"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkad005"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae079"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae053"},{"key":"e_1_2_10_28_1","unstructured":"https:\/\/tripsit.me\/factsheets\/bromazolam."},{"key":"e_1_2_10_29_1","unstructured":"BNF https:\/\/bnf.nice.org.uk\/treatment\u2010summaries\/hypnotics\u2010and\u2010anxiolytics\/."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706796"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211026645"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.70045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:26:37Z","timestamp":1775031997000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.70045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/dta.70045"],"URL":"https:\/\/doi.org\/10.1002\/dta.70045","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-26w75","asserted-by":"object"}]},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2025-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}